INTRODUCTION
Oxygen saves lives. Its provision is a critical component of emergency respiratory resuscitation around the world, and it consequently features on the WHO’s list of essential medicines. Oxygen therapy is not just used for pneumonia and other lung diseases. It is also crucial for treating various non-respiratory conditions that result in hypoxaemia, such as sepsis, severe malaria, trauma and cardiovascular diseases. It is equally essential for surgical care and anaesthesia.

In Western countries, the reaction to the COVID-19 pandemic has been to increase hospital capacity and to provide more intensive care units (ICUs) and more ventilators. There had been little discussion of the provision of oxygen as this is a standard clinical tool widely available in hospitals. This is not the case in sub-Saharan Africa (SSA). There is a shortage of oxygen in health centres in SSA. When it comes to prioritising medical resources, SSA needs to save the maximum number of lives during the COVID-19 pandemic; arguably, two things should be atop of that list before ICUs and ventilators. These are personal protective equipment (PPE) for frontline health workers and oxygen for the patients. The need for PPE is a global issue and one whose importance has been highlighted in the different health systems as it is critical to ensure frontline health workers are protected from COVID-19 infection and that they are not infection conduits within hospitals.

Oxygen, on the other hand, has received less attention, and yet it is the second most important aspect of the COVID-19 response. Critically, pneumonia is a predominant clinical feature of COVID-19, and adequate ventilation support is essential for patient survival. It has been indicated that supplemental oxygen is a first essential step for the treatment of patients with severe COVID-19 with hypoxaemia and should be a primary focus in resource-limited settings. In China, a study of 1099 hospitalised patients with laboratory-confirmed COVID-19 this year found that 41.3% needed supplemental oxygen and 2.3% needed invasive mechanical ventilation. Therefore, investing in supplementary oxygen would strengthen the response to COVID-19 in African countries and save lives.

Prior to the COVID-19 pandemic several countries in SSA were already suffering from shortages of oxygen, shortages of equipment, as well as lack of training to support the correct and optimal use of oxygen therapy especially for the treatment of paediatric pneumonia. For example, in 2018, only 1 in 10 children with pneumonia in Nigeria received the oxygen they needed. In Kenya, many rural hospitals lack supplementary oxygen equipment, adequate supply chains for oxygen cylinders and reliable electrical power needed for oxygen delivery. The impact of such shortages during an epidemic were illustrated during the response to influenza. Even when available, the cost of oxygen in SSA can be prohibitive and prices fluctuate widely, often depending on whether or not production sites are nearby. For example, 6.8 m3 of oxygen (provision for an adult for 24 hours) can reach up to $100 in Somalia.
NEED FOR OXYGEN TO FIGHT COVID-19 IN SSA

By modelling the epidemic in each sub-Saharan African country every week (see http://tiba-partnership.org/), we have been able to calculate doubling times for the COVID-19 epidemic, providing important evidence to inform planning and resource mobilisation. We can calculate the oxygen requirements for each country, using the doubling times of diseases spread and the current clinical knowledge available on COVID-19 to calculate a mean oxygen requirement per patient. On the African continent, the COVID-19 pandemic has doubled in size in 10 days up to 16 April. With only two countries in Africa, Ethiopia and Nigeria having oxygen policy roadmaps, other African countries and their global partners need to put together a rapid plan to supply oxygen to all countries in the region in order to save lives.

Although the majority of people with COVID-19 have uncomplicated or mild illness, WHO currently estimates that around 14% of cases may be severe and that an additional 5% will be critical and require treatment in ICUs. WHO recommends the immediate supply of an additional 5% will be critical and require treatment mates that around 14% of cases may be severe and that need to put together a rapid plan to supply oxygen to all countries in the region in order to save lives.

Whether or not these patients receive oxygen will be decisive for their survival. It has been observed in the UK that for the hospitalised patients with COVID-19 who require high levels of supplemental oxygen, it is life-saving in approximately 80% of the cases. Due to the anticipated large number of people in SSA who will likely require oxygen and the great impact this will likely have on their survival, its provision—together with that of oximeters and oxygen-delivering interfaces—should be made a regional priority.

CONTEXT-RELEVANT SOLUTIONS TO OXYGEN SUPPLY

WHO indicates fewer than 2000 working ventilators exist in 41 African countries to serve hundreds of millions of people in public hospitals, compared with more than 170,000 in the USA. Ten countries in Africa have no ventilators at all. Ventilators are not going to be the solution for the majority of patients with COVID-19 in Africa for two reasons. First, only a small number (<3%) of patients with COVID-19 need ventilators. Second, if there is no oxygen to put in the ventilators, they cannot be used. Allocating resources to widespread oxygen provision will save more lives.

Medical oxygen is a regulated commodity that must be at least 92% pure, free from any contamination and generated by an oil-free compressor. It can come from oxygen plants, liquid oxygen storage tanks or oxygen concentrators. In SSA, there are two main sources of oxygen: concentrators and cylinders (see table 1). While concentrators are the cheapest and most scalable way to supply oxygen, they require a functioning infrastructure with reliable power supply (although some countries have solved this problem by using solar-powered concentrators as detailed further), as well as regular servicing. In addition, the level of oxygen flow that they can deliver (usually between 5 and 10 L/min) can also be insufficient for severe patients requiring 15 L/min, yet they may be used to ease demand on cylinders, which can be directed to patients with severe COVID-19. The more expensive cylinders require neither a power source nor costly maintenance. Clinicians in some SSA health systems have indicated that the priority list would include first pulse oximeters to measure oxygen levels, followed by oxygen concentrators that can be used in small healthcare settings and finally higher-tech equipment like ventilators.

SOME SOLUTIONS FROM AFRICAN COUNTRIES FOR BUILDING OXYGEN SUPPLY

The problem is not insurmountable. Home-grown innovation is allowing some African countries to address the oxygen supply challenges. For example, a 42-bed hospital in the Gambia has managed to ensure uninterrupted oxygen supply for 8 years straight, using oxygen concentrators (rather than the more expensive cylinders). In Kenya, a county government enabled the construction of an oxygen plant by a private company, while the hospital commissioning the plant committed

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Comparison of oxygen cylinders and concentrators (adapted from Graham et al)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oxygen cylinders</strong></td>
<td><strong>Oxygen concentrators</strong></td>
</tr>
<tr>
<td>Capital cost</td>
<td>Low (higher if including regulators and flow-meter assemblies)</td>
</tr>
<tr>
<td>Running cost</td>
<td>High: frequent refilling, transport and logistics</td>
</tr>
<tr>
<td>Power source</td>
<td>None required</td>
</tr>
<tr>
<td>Reliability</td>
<td>Good, so long as supply lasts</td>
</tr>
<tr>
<td>Continuous supply</td>
<td>No, limited by volume (large H-type cylinders last 2–4 days with continuous low-flow use)</td>
</tr>
<tr>
<td>Maintenance</td>
<td>Minimal: check regulators, leakage</td>
</tr>
<tr>
<td>Training</td>
<td>Yes, clinical use of oxygen, care of cylinders and connections</td>
</tr>
</tbody>
</table>
in advanced to buying a fixed oxygen quota.\textsuperscript{18} In Ethiopia, a garment manufacturer that produces oxygen for bleaching purposes aims to provide it to a nearby hospital, reflecting technology spillover.\textsuperscript{15} In Uganda, solar-powered oxygen delivery for rural settings has been developed to overcome issues of unreliable power supply.\textsuperscript{10} Solar-powered systems can turn ambient air into medical-grade oxygen with battery banks, enabling uninterrupted service through the night and on cloudy days. Provided they come with ‘roadmaps’ for local procurement, training and maintenance, they can be used in off-grid settings.\textsuperscript{20} To deal with the shortage of ventilators, Senegal is pioneering the use of 3-D printed ventilators costing ~US$60.\textsuperscript{21} These initiatives clearly demonstrate the successes of partnerships between governments, the private sector and hospitals to urgently increase regional oxygen availability. Development partners should be prioritising support for these local initiatives whose long-term impact and health legacy will outlast the COVID-19 pandemic.

CONCLUSION

The recovery of critically ill patients with COVID-19 will require oxygen. Available evidence supports prioritising investment in oxygen infrastructure, not only for COVID-19 and severe acute respiratory infections but also for other conditions that cause hypoxaemia. African countries should develop oxygen roadmaps that prioritise procurement of equipment, such as oxygen concentrators or high-pressure cylinders and oxygen from local industry. Examples from African countries demonstrate that oxygen provision can be scaled up through innovative cheap technologies. Responses by development partners and funders for local, context-specific solutions to the region’s oxygen supply shortages are encouraging. They need to be accelerated.

Acknowledgements  We are grateful to Professor Tom Evans from the University of Glasgow for reviewing an earlier draft of this manuscript. This work was commissioned by the National Institute for Health Research (NIHR) Global Health Research programme (16/136/33) using UK aid from the UK Government. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Contributors  FM has conceived of the work and substantially contributed to its writing and analysis. FS has substantially contributed to its writing and analysis. MW, GB and MP have substantially contributed to the analysis. All five authors have drafted and revised the text. They all have provided final approval of the version to be published and agreed to be accountable for all aspects of the work with respect to its accuracy and research integrity.

Funding  The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests  None declared.

Patient consent for publication  Not required.

Provenance and peer review  Not commissioned; externally peer reviewed.

Data availability statement  No additional data are available.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Author note  TIBA twitter handle @TibaPartnership

ORCID iD  Felix Stein http://orcid.org/0000-0002-0123-9895

REFERENCES

14. Numbers based on personal communication with Infectious Diseases specialists from NHS Scotland.
